In conclusion, this study highlights the effective role of combining GLP-1 and GIP/GLP-1 agonists with a continuous, digitally delivered behavioral change model by an integrated care team in managing MetS, particularly in reducing WC, improving lipid profiles, and enhancing glycemic control across different genders. This evidence concerns the gene GIP and metabolic syndrome.